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Abstract
Objectives
To explore associations between exposure to antidepressants, their discontinuation,
depression [medicated or unmediated] and preterm birth [<37 and <32 weeks], small for
gestational age (SGA) [<10th and <3rd centiles], breastfeeding [any] at 6–8 weeks.
Methods
Design: A population-based cohort study.
Setting: The Secure Anonymised Information Linkage [SAIL] databank in Wales, linking
maternal primary care data with infant outcomes.
Participants: 107,573, 105,331, and 38,725 infants born 2000–2010 with information on
prematurity, SGA and breastfeeding respectively, after exclusions.
Exposures: Maternal antidepressant prescriptions in trimesters 2 or 3, discontinuation after
trimester 1, recorded diagnosis of depression [medicated or unmediated] in pregnancy.
Methods: Odds ratios for adverse pregnancy outcomes were calculated, adjusted for smok-
ing, parity, socio-economic status, and depression.
Results
Exclusive formula feeding at 6–8 weeks was associated with prescriptions in trimesters 2 or
3 for any antidepressants (adjusted odds ratio [aOR] 0.81, 95% confidence intervals 0.67–
0.98), SSRIs [aOR 0.77, 0.62–0.95], particularly higher doses [aOR 0.45, 0.23–0.86], dis-
continuation of antidepressants or SSRIs after trimester 1 (aOR 0.70, 0.57–0.83 and 0.66,
0.51–0.87), diagnosis of depression aOR 0.76 [0.70–0.82), particularly if medicated (aOR
0.70, 0.58–0.85), rather than unmedicated (aOR 0.87, 0.82–0.92). Preterm birth at <37 and
<32 weeks’ gestation was associated with diagnosis of depression (aOR 1.27, 1.17–1.38,
and 1.33, 1.09–1.62), particularly if medicated (aOR 1.56, 1.23–1.96, and 1.63, 0.94–2.84);
birth at <37 weeks was associated with antidepressants, (aOR 1.24, 1.04–1.49]. SGA <3rd
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centile was associated with antidepressants (aOR 1.43, 1.07–1.90), and SSRIs (aOR 1.46,
1.06–2.00], particularly higher doses [aOR 2.10, 1.32–3.34]. All adverse outcomes were
associated with socio-economic status and smoking.
Implications
Exposure to antidepressants or depression increased risks of exclusive formula feeding at
6–8 weeks, and prescription of antidepressants was associated with SGA <3rd centile. Pre-
scription of antidepressants offers a useful marker to target additional support and addi-
tional care before and during pregnancy and lactation.
Introduction
Some 20% women aged 16–54 report at least one common mental health problem: this figure
[point prevalence of 19.5–25.2%] has remained unchanged since 2000. [1] The prevalence of
depression during pregnancy is reported as between 6 and 13%,[2, 3] and around 10% preg-
nant women develop a depressive illness during pregnancy or postpartum, with a further 16%
developing a self-limiting depressive reaction. [4]
Selective serotonin reuptake inhibitors [SSRIs] are the most commonly prescribed antide-
pressants: [5,4] 2.8% [6] to 10.2%[7] pregnant women are prescribed SSRIs during pregnancy,
with marked variation across Europe. [8] SSRIs, and their metabolites, cross the placenta, [9]
and appear in cord blood [10, 11] in proportion to dose administered; [12] foetal exposure is
prolonged by accumulation in amniotic fluid. SSRIs, and some other antidepressants, act on
the crucial serotonin transporter [SERT, aka 5HTT, SLC6A4, OMIM 182138], increasing the
bioavailability of serotonin [5HT] in many tissues, including the placenta. [13] Serotonin-
induced vasoconstriction [11, 14, 15] reduces placental blood flow, leaving the foetus vulnera-
ble to intra-uterine growth retardation. Serotonin may also promote preterm birth by its
uterotonic actions. [16]
The dose-response relationship between SSRI prescriptions in trimester 1 and the adverse
outcome ‘major congenital anomaly and/ or stillbirth’ [17] is a concern, but the effects of SSRI
exposure, discontinuation and depression on the range of pregnancy outcomes, including lac-
tation, need to be considered together. Observation studies indicate increased risks of sponta-
neous abortion [18] low birth weight [19], prematurity [20, 21, 22], admission to neonatal
special care facilities, [23] gestational hypertension, [24] and persistent pulmonary hyperten-
sion in neonates. [25, 26] However, despite biological plausibility, not all studies report an
increase in preterm birth, [27] and poor parental perinatal mental health can adversely affect
childhood outcomes. [27]
Many studies are unable to account for the effects of underlying mental illness, discontinua-
tion of medication, social stress or smoking and some associations with adverse outcomes may
be shared with non-SSRI antidepressants [28] or depressive illness. [29] Consequently, the key
question for women and clinicians—the harm to benefit balance of starting, stopping or con-
tinuing antidepressant pharmacotherapy [5]—remains unanswered. Accordingly, the aim of
this study is to investigate any associations between antidepressants, SSRIs at standard and
higher doses, their discontinuation after trimester 1, and depression [medicated or unmedi-
cated] and the range of adverse outcomes important to women: preterm birth, intra-uterine
growth as SGA and, for the first time, breastfeeding [any] at 6–8 weeks, complementing
reports of increased prevalence of congenital anomalies [17].
Antidepressants and perinatal outcomes, including breastfeeding
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Methods
A population-based cohort was built from prospectively collected routine NHS data and ana-
lysed retrospectively.
Ethics
The Secure Anonymised Information Linkage [SAIL] Databank Information Governance
Review Panel [IGRP] approved the study on behalf of the National Research Ethics Service,
Wales on 24th March 2011. Data were irrevocably anonymised and obtained with permission
of the relevant Caldicott Guardian and Data Protection Officer [30].
Setting
Data were extracted from existing routinely collected data in SAIL, housed in Swansea Univer-
sity. Within SAIL, we linked primary care records, including prescriptions, for the ~40% of the
population whose general practitioners (GPs) had agreed to share data with SAIL, without pay-
ment, by 2014. [31,32] to: the Office of National Statistics births and deaths register, the
National Community Child Health Database [NCCHD] [http://www.wales.nhs.uk/news/
28291], the Patient Episode Database for Wales [http://www.wales.nhs.uk/document/176173],
CARIS [Congenital Anomaly Register and Information Service for Wales] [http://www.caris.
wales.nhs.uk/home]. Databases were linked by a trusted third party [NHS Wales Informatics
Service [NWIS], [http://www.wales.nhs.uk/sitesplus/956/home], using unique personal identi-
fiers, which remained undisclosed to researchers, ensuring anonymity. [33]
Population
The study population included all births in Wales after 24 gestational weeks between 1st Janu-
ary 2000 and 31st December 2010, with linked maternal prescription data. Infants were
included where the associated maternal ID could be linked with the primary care dataset,
which was dependent on the general practice, and the record was complete. [33] We included
all infants where the woman was present in the linked database with primary care prescription
information 91 days before last menstrual period [LMP] to birth. Information on start of preg-
nancy was obtained from ultrasound scan data recorded in the NCCHD. [33]
Exposure
Exposure was defined as one or more prescription for an antidepressant issued between 92 days
after the first day of LMP and birth [Table 1]. We based our timeframe on prescription duration
[typically 90 days] and relevant pharmacokinetic parameters: for example, elimination of the
active metabolite of fluoxetine can take ~40 days in adults, [34] and longer in the embryo or foe-
tus. [35] Antidepressants were investigated according to anatomical, therapeutic, chemical
[ATC] classification grouped: a] all SSRIs [N06AB]; b] all serotonin and norepinephrine reup-
take inhibitors (SNRIs) [N06AX]; c] all antidepressants, including SSRIs and SNRIs [N06A].
Depression was defined as any diagnosis of depression in the woman’s record before the
end of trimester 1 [91 days after 1st day of LMP], recorded by the GP using Read codes, ver-
sion 2 [17,36, 37] (S1 File). Vulnerability and kindling hypotheses [38] suggest that any episode
of depression may predispose to recurrence during pregnancy [39] with associated stressor-
induced release of inflammatory cytokines, and any episode of depression permanently
changes the hippocampus, prefrontal cortex neurochemistry and fronto-cingulate connec-
tions: [38] accordingly, we did not time-limit depression exposure. Medicated and unmedi-
cated depression were defined as a recorded diagnosis of depression, with / without any
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antidepressant prescribed in trimesters 2 or 3. Discontinuation was defined as�1 prescription
during trimester 1 and no further prescriptions recorded throughout pregnancy [Table 1].
Other indications for antidepressants recorded were: post-traumatic stress disorder [PTSD],
obsessive compulsive disorder [OCD], panic disorder, bulimia, general and social anxiety dis-
orders. We ascertained whether women had been admitted to hospital with a mental health
diagnosis or had contacted community mental health teams [CMHTs] before [any time], dur-
ing or up to 1 year after pregnancy.
Dose was not directly available, so tablet and capsule strengths were taken as proxies. We
classified high dose SSRI exposure as prescription of: 60mg fluoxetine, 40mg citalopram, 30mg
paroxetine, 100mg sertraline, 20mg escitalopram, based on tablet/ capsule sizes quoted in the
British National Formulary. [40] Smaller tablets and capsules were classified as ‘other dose’
[low or medium]. [33]
Outcomes
Prematurity was defined as<37, and extreme prematurity as<32 completed weeks’ gestation.
[41] Growth centiles were calculated from WHO standards for the UK, and infants below the
10th and 3rd centiles were identified; the latter category is defined as 2 standard deviations
below the median. [42]
Breastfeeding [any, even if supplemented by formula feeding] at birth and 6–8 weeks is rou-
tinely recorded by health visitors, and this information is transferred to NCCHD; data
Table 1. Classification of exposures.
Exposure ATC Timeframe
SSRI [any]
�1 SSRI [any] prescription in trimesters 2 or 3
N06AB From 92 days after the first day of LMP to birth
High dose SSRI
�1 high dose SSRI [any] prescription t2-3 [defined as tablet sizes:
60mg fluoxetine, 40mg citalopram, 30mg paroxetine, 100mg sertraline,
20mg escitalopram]
N06AB From 92 days after the first day of LMP to birth
Antidepressant [any]
�1 Antidepressant prescription trimesters 2 or 3 t2-3�
N06A From 92 days after the first day of LMP to birth
SNRI [any]
�1 prescription for an SNRI in trimesters 2 or 3
Venlafaxine N06AX16,
reboxetine N06AX18, duloxetine
N06AX21
From 92 days after the first day of LMP to birth
Depression diagnosis in the primary care record whilst on the database - Any time before the end of trimester 1 [91 days after 1st
day of LMP]
Unmedicated depression Depression diagnosis recorded [as above] but no
antidepressant prescribed in trimesters 2 or 3 [t2-3].
Medicated depression N06A Depression diagnosis recorded [as above] plus an
antidepressant in trimesters 2 or 3 [t2-3].
Discontinued SSRI:
�1 SSRI prescription in trimester 1, but not in trimesters 2 or 3
N06AB Prescription between 1st day LMP and 91 days after 1st
day LMP] and no further prescriptions recorded
throughout pregnancy
Discontinued antidepressant:
�1 prescription of any antidepressant in trimester 1, but not in
trimesters 2 or 3
N06A Prescription between 1st day LMP and 91 days after 1st
day LMP] and no further prescriptions recorded
throughout pregnancy
LMP—last menstrual period, SSRI–selective serotonin reuptake inhibitor, SNRI–serotonin and noradrenaline reuptake inhibitor
Medicines were defined by ATC codes, and then matched to version 2 Read codes in the GP database, using reference data provided by NHS Digital Technology
Reference Data Update Distribution [https://isd.digital.nhs.uk/trud3/user/guest/group/0/home].
Depression was captured from Read codes https://www.datadictionary.nhs.uk/web_site_content/supporting_information/clinical_coding/read_coded_clinical_terms.
asp?shownav=1 listed in S1 File.
https://doi.org/10.1371/journal.pone.0225133.t001
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collection is more complete in some Health Boards than others. [43] Breastfeeding at birth is
considered an indirect measure, which may represent intention rather than practice, and may
not indicate successful breastfeeding; [44] we report data at 6–8 weeks. Data were available
from 2004, reducing the sample size.
Confounding
To minimise confounding by co-exposure, we excluded pregnancies known to be at increased
risk of adverse outcomes. We achieved a relatively homogeneous population by excluding
from the main analysis infants: 1) with major congenital anomalies [as defined by EUROCAT;
[45] 2) from multiple pregnancies; 3) stillborn; 4) whose mothers were prescribed medicines
more closely associated with adverse outcomes than antidepressants in trimester 1 or the quar-
ter preceding pregnancy: anti-epileptic drugs [AEDs] [N03]; [46] coumarins [B01AA], mainly
warfarin [47]; insulins [A10A]; [48] and 5) whose mothers had any record of: heavy alcohol
use and/or substance misuse. [49] We did not exclude moderate alcohol use as this is not
known to affect perinatal outcomes, [49] and may be inconsistently recorded. To minimize
confounding by indication, we adjusted analyses for depression [any recorded diagnosis],
[38] and investigated depression, both medicated and unmedicated, discontinuation of medi-
cation and higher doses separately. We also adjusted for socioeconomic status [SES], as Town-
send fifths (Tables A1, A2 in S2 File), parity, smoking [as ‘yes’ or ‘no’], and year of birth. In
this cohort, SES is associated with antidepressant prescriptions, depression and maternal age
at birth. [17,50] Where confounders are correlated, the odds ratios are less vulnerable to bias
[51]. Therefore, in view of the low numbers in some outcomes, to reduce co-linearity with SES
and parity, age [a non-modifiable risk factor] was not entered into the regression analyses.
There were too few women aged>39 at birth to explore this potentially high risk group
separately.
Statistical analysis
We explored associations between prematurity, SGA and breastfeeding and: a)�1 prescrip-
tion in trimesters 2 or 3 of any antidepressant, and SSRIs at any and high doses; b) discontinu-
ation of SSRI or antidepressant after trimester 1; c) depression, medicated or unmedicated.
Outcomes with sufficient numbers of exposed pregnancies were explored by multivariate
logistic regression, backwards likelihood ratio [52], with covariates SES [53], parity, smoking,
year of birth, and, where appropriate, depression using SPSS version 25 for windows [IBM
Corp 2011]. [54] Interaction variables ‘depression�SSRI’ or ‘depression�antidepressant’ were
entered into the models to test the independence of the diagnosis and the prescription. Where
associations were statistically significant, numbers needed to harm [NNH] were calculated, to
aid interpretation of findings. We explored demographic differences between the women with
and without breastfeeding data at 6–8 weeks.
Results
After exclusions, 107,573, 105,331, and 38,725 infants available for analysis on prematurity,
SGA and breastfeeding [Fig 1]. Adverse outcomes were more prevalent and breastfeeding
rates were lower in infants exposed to insulin, AEDs, coumarins substance misuse or heavy
alcohol use [Tables B1, B2 in S2 File]. Some 2% women prescribed antidepressants were co-
exposed to AEDs, and exposure to insulin, smoking, substance misuse or heavy alcohol use
was more prevalent than in the population. Co-exposures with diagnosed depression was
slightly lower. Both depression and antidepressant prescriptions were more prevalent amongst
the most economically deprived and the most obese [BMI>30] [Tables A1, A2 in S2 File].
Antidepressants and perinatal outcomes, including breastfeeding
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In trimesters 2 or 3, 1625 [1.5%] women were prescribed SSRIs, [538 at high doses], and
2043 [1.9%] an antidepressant. Of these, 836 [51.4%] and 1048 [51.3%] had a diagnosis of
depression. 12,748 women had been diagnosed with depression at some point. Many women
diagnosed with post-traumatic stress disorder [PTSD], obsessive compulsive disorder [OCD],
panic disorder, bulimia, general and social anxiety disorders were also diagnosed with depres-
sion. Of the 2394 women diagnosed with any of these conditions, but not depression, 141
[5.89%] were prescribed an antidepressant in trimesters 2 or 3, indicating that 854 [2043-1048-
141] [41.80%] recipients of antidepressants had no recorded indication for their prescriptions.
Most (4252/6295, 67.55%) women prescribed antidepressants in trimester 1 had no further
prescriptions in trimesters 2 or 3: of these, 2076 [48.8%] had a diagnosis of depression, and
2285 were prescribed an SSRI. In the entire cohort (107,573), nine women were admitted to
hospital with a mental health diagnosis during pregnancy, and 18 in the year following child-
birth. Eleven or the 27 women admitted had discontinued an antidepressant after trimester 1,
representing 0.26% of the 4252 discontinuing. Some [numbers too low for disclosure] had
contacted their CMHTs. Of the 4252 women discontinuing antidepressants, 163 (3.93%) had
contacted CMHTs during, and 127 (2.99%) after pregnancy.
All exposures were associated with increased prevalence of at least some adverse outcomes.
Not all associations were statistically significant. There were low numbers of infants in the
extreme prematurity, <3rd centile, high dose and medicated depression categories. Economic
deprivation, smoking and primiparity were associated with SGA and prematurity; only breast-
feeding was associated with year of birth [Tables C-E in S2 File].
Preterm birth, before 37 and 32 weeks’ gestation, was associated with a diagnosis of depres-
sion [aOR 1.27, 1.17–1.38, NNH 69, 52–101 and 1.33, 1.09–1.62, NNH 389, 222–1451], partic-
ularly medicated depression [aOR 1.56, 1.23–1.96], NNH 30, 20–62, and aOR 1.63, 0.94–2.84].
Birth at<37 weeks’ was associated with any antidepressant in trimesters 2 or 3 [1.24, 1.04–
1.49, NNH 44, 29–90]. Associations with SSRI prescription were not statistically significant.
Prevalence of birth at<32 weeks’ was highest with medicated depression and high dose SSRIs,
but associations did not reach statistical significance. There was no increased risk if antidepres-
sants were discontinued after trimester 1 [Tables 2 and 3].
Birth weight below 3rd centile was associated with SSRI or any antidepressant prescription
in trimesters 2 or 3 [aOR 1.46, 1.06–2.00, NNH 81, 48–261 and 1.43, 1.07–1.90, NNH 90, 54–
275], particularly high dose SSRIs [aOR 2.10, 1.32–3.34, NNH 40, 24–130]. Associations with
diagnosed depression or discontinuation of medication after trimester 1 were statistically
insignificant. SGA <10th centile was only statistically significantly associated with discontinu-
ation of antidepressants [Tables 4 and 5].
At 6–8 weeks, breastfeeding [any] was less prevalent amongst those prescribed SSRIs [aOR
0.77, 0.62–0.95, NNH 9, 7–12], particularly high doses [aOR 0.45, 0.23–0.86, NNH 9, 6–18], or
any antidepressants in trimesters 2 and 3 [aOR 0.81, 0.67–0.98, NNH 10, 8–13]. Depression
was an equally important predictor of exclusive formula feeding [aOR 0.76, 0.70–0.82, NNH
12, 11–14], and discontinuation of SSRIs or antidepressants after trimester 1 offered no benefit
in terms of predicting breastfeeding success [aOR 0.66, 0.51–0.87, NNH 11, 9–16 and 0.70,
0.57–0.85, NNH 10, 8–13]. Medicated depression appeared a stronger predictor of exclusive
formula feeding than unmedicated depression [Table 6]. High SES, non-smoking and nulli-
parity predicted breastfeeding at 6–8 weeks. Associations with breastfeeding at birth were sim-
ilar [Tables D, E in S2 File].
Interaction terms between depression and prescribed medicines were statistically significant
for: discontinuing SSRIs and breastfeeding, gestation<37 weeks, and<10th centile; high dose
SSRIs and breastfeeding,<37 weeks; discontinuing any antidepressant and breastfeeding,<37
weeks and birth weight<10th centile. Interaction terms were not statistically significant for
Antidepressants and perinatal outcomes, including breastfeeding
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prescription of SSRIs or antidepressants and prematurity, SGA or breastfeeding, indicating that
the impact of depression and the prescriptions were independent of each other (Tables 2–6).
Seventy-three infants were exposed to SNRIs in trimesters 2 & 3, including 49 whose moth-
ers had been diagnosed with depression. None of these was born before 32 weeks, <5 were
below the 3rd centile, OR>2, but not statistically significant, and 6 were breastfeeding at 6–8
weeks, OR 2.39 [0.99–5.75]. Unadjusted analysis indicated a significant association with birth
at<37 weeks, OR 2.93 [1.54–5.56], and a non-significant association with<10th centile OR
1.30 [0.52–3.21]. [Numbers were too low for adjusted analyses.] Too few women were diag-
nosed with PTSD, OCD, panic disorder, bulimia, general and social anxiety disorders for
exploration. Women with breastfeeding data were older than those without [mean ages 28.48
Fig 1. Study flow diagram.
https://doi.org/10.1371/journal.pone.0225133.g001
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Table 2. Preterm birth @<37 weeks’ gestation (n = 107573).
Exposures Exposed n [%] Unexposed n [%] Unadjusted OR
[95% CI]
Adjusted� OR
[95% CI]
NNH Interaction term with
depression variable
SSRI [any N06AB] in trimesters 2 or 3 124/1625
[7.63]
6033/105,948
[5.69]
1.37[1.14–1.65] 1.19[0.97–1.46] Ns 1.03[0.68–1.54]
SSRI high dose in trimesters 2 or 3 38/538 [7.06] 6119/107,035
[5.72]
1.25[0.90–1.75] 1.05[0.72–1.53] Ns 1.27[1.17–1.37]
Antidepressant [any N06A] in trimesters
2 or 3
163/2043
[7.98]
5994/105,530
[5.68]
1.44[1.24–1.63] 1.24 [1.04–1.49] 44 [29–
90]
0.90[0.63–1.30]
SSRI in trimester 1 but not in trimesters
2 or 3
165/2285
[7.22]
5992/ 205,288
[5.69]
1.29[1.10–1.51] 1.00[0.77–1.30] Ns 1.28[1.18–1.38]
Antidepressant in trimester 1 but not in
trimesters 2 or 3
306/4252
[7.2]
5851/103,321
[5.66]
1.29[1.15–1.46] 0.99[0.82–1.21] Ns 1.28[1.19–1.39]
Depression unmedicated 812/11,700
[6.94]
5345/95,873
[5.58]
1.26[1.17–1.36] 1.23[1.13–1.34] 74 [55–
115]
NA
Depression medicated 95/1048
[9.06]
6062/10,652
[5.69]
1.65[1.34–2.04] 1.56[1.23–1.96] 30 [20–
62]
NA
Depression diagnosed 907/12,748
[7.11]
5250/94,034
[5.54]
1.30[1.22–1.41] 1.27[1.17–1.38] 69 [52–
101]
NA
�Adjusted for parity, smoking, socio-economic status [SES] as Townsend fifth [quintile].
Exclusions from analysis: all congenital anomalies, terminations of pregnancy for foetal anomalies [TOPFA], stillbirths, multiple births [twins, triplets and quadruplets
[no higher multiples in the dataset]],�1 prescription for insulin, anti-epileptic drugs [AEDs] or coumarins in the quarter preceding pregnancy and trimester 1, heavy
drinking/substance misuse [any record].
Deprivation [Townsend] scores, ranks and fifths are based on geographical area of residence, using Lower Super Output Areas [LSOAs] defined by residential
postcodes. This measure of material deprivation is calculated from rates of unemployment, vehicle ownership, home ownership, and overcrowding]. [54]
Abbreviations and definitions are listed in Table 1.
OR odds ratio, CI confidence intervals, NNH number needed to harm, Ns not statistically significant.
https://doi.org/10.1371/journal.pone.0225133.t002
Table 3. Preterm birth @<32 weeks’ gestation (n = 107573).
Prescriptions Exposed n [%] Unexposed n
[%]
Unadjusted OR [95%
CI
Adjusted� OR
[95% CI]
Interaction term with
depression variable
SSRI [any N06AB] in trimesters 2 or 3 20/1625 [1.23] 913/105,948
[0.86]
1.43 [0.92–2.24] 1.24 [0.76–2.03] 1.04(0.39–2.81)
SSRI high dose in trimesters 2 or 3 7/538 [1.3] 926/107035
[0.87]
1.51 [0.72–3.19] 1.74 [0.55–5.46] 0.69[0.17–2.82]
Antidepressant [any N06A] in trimesters
2 or 3
23/2043 [1.13] 910/105,530
[0.86]
1.31 [0.86–1.99] 1.15 [0.73–1.81] 1.31(0.73–2.34)
SSRI in trimester 1 but not in trimesters 2
or 3
25/2285 [1.09] 908/105288
[0.86]
1.27 [0.85–1.90] 0.88 [0.48–1.60] 1.09[0.54–2.20]
Antidepressant in trimester 1 but not in
trimesters 2 or 3
48/4252 [1.13] 885/103,321
[0.86]
1.32 [0.99–1.77] 1.11 [0.80–1.55] 0.85[0.44–1.65]
Depression unmedicated 127/11,700 [1.09] 806 [0.84] 1.29 [1.07–1.56] 1.29[1.05–1.58] na
Depression medicated 15/1048 [1.43] 918/10,652
[0.86]
1.67[1.00–2.79] 1.63 [0.94–2.84] na
Depression diagnosed 139–142��/12,748
[1.09–1.11]
791/94,034
[0.84]
OR> 1 statistically
significant
1.33 [1.09–1.62] na
Exclusions, definitions and abbreviations as in Table 2
�Adjusted for parity, smoking, socio-economic status [SES] as Townsend fifth [quintile].
NNH for depression diagnosed and unmedicated 409 [227–2070].
�� Numbers have been blurred to avoid revealing a number <5 in another cell.
https://doi.org/10.1371/journal.pone.0225133.t003
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[6.09] vs. 28.04 [6.04] years, mean difference 0.44 [0.36–0.51], t 11.36, df 79659, p<0.001],
more deprived [mean Townsend score 0.40 [3.24] vs. 0.21 [3.12], mean difference 0.20 [0.16–
0.24], t 9.65, df 77578, p<0.001], and less likely to be primiparous [16095/38725, 41.6% vs.
29388/68848, 42.7% OR 0.96 [0.93–0.98].
Table 4. SGA, birth weight<10th centile (n = 105331).
Exposures Exposed n [%] Unexposed [n
[%]
Unadjusted OR [95%
CI
Adjusted� OR [95%
CI]
Interaction term with depression
variable
SSRI [any N06AB] in trimesters 2 or 3 166/1587
[10.46]
8991/103,744
[8.67]
1.23 [1.05–1.45] 1.09 [0.91–1.30] 0.88(0.69–1.13)
SSRI high dose in trimesters 2 or 3 63/525 [12] 9094/104,806
[8.68]
1.44 [1.10–1.87] 1.30 [0.98–1.74] 0.85[0.47–1.53]
Antidepressant [any N06A] in trimesters 2 or
3
204/1993
[10.24]
8953/103,338
[8.66]
1.20 [1.04–1.39] 1.07 [0.91–1.25] 0.96(0.70–1.33)
SSRI in trimester 1 but not in trimesters 2 or
3
229/2234
[10.25]
8928/103,097
[8.66]
1.21 [1.05–1.38] 1.27(1.03–1.57) 0.76(0.56–1.03)
Antidepressant in trimester 1 but not in
trimesters 2 or 3
418/4156
[10.06]
8739/101,175
[8.64]
1.18 [1.07–1.31] 1.23 [1.04–1.44] 0.79[0.62–0.99]
Depression unmedicated 1070/11,435
[9.36]
8087/93,896
[8.61]
1.10 [1.02–1.17] 1.04[0.97–1.12] Na
Depression medicated 107/1024
[10.45]
9050/104,307
[8.68]
1.23 [1.00–1.50] 1.13 [0.91–1.41] Na
Depression diagnosed 1177/12,459
[9.45]
7980/92,872
[8.59]
1.11 [1.04–1.18] 1.05 [0.98–1.13] Na
Exclusions, definitions and abbreviations as in Table 2
�Adjusted for parity, smoking, socio-economic status [SES] as Townsend fifth [quintile].
NNH for any antidepressant discontinuation 71 [43–204].
https://doi.org/10.1371/journal.pone.0225133.t004
Table 5. SGA, birth weight<3rd centile (n = 105331).
Exposures Exposed n
[%]
Unexposed [n
[%]
Unadjusted OR
[95% CI]
Adjusted�
OR
[95% CI]
Number Needed to
Harm
Interaction term with
depression variable
SSRI [any N06AB] in trimesters 2 or 3 49/1587
[3.09]
1918/103,744
[1.85]
1.69 [1.27–2.26] 1.46 [1.06–
2.00]
81 [48–261] 1.11(0.59–2.11)
SSRI high dose in trimesters 2 or 3 23/525 [4.38] 1944/104,806
[1.85]
2.42 [1.59–3.69] 2.10 [1.32–
3.34]
40 [24–130] 0.76[0.29–2.01]
Antidepressant [any N06A] in
trimesters 2 or 3
59/1993
[2.96]
1908/103,338
[1.85]
1.62 [1.25–2.11] 1.43 [1.07–
1.90]
90 [54–274] 1.14(0.64–2.03)
SSRI in trimester 1 but not in
trimesters 2 or 3
45/2234
[2.01]
1922/103,097
[1.86]
1.08 [0.80–1.46] 1.11 [0.72–
1.71]
Ns 0.69[0.36–1.33]
Antidepressant in trimester 1 but not in
trimesters 2 or 3
92/4156
[2.21]
1875/101.175
[1.85]
1.20 [0.97–1.48] 1.12 [0.80–
1.55]
Ns 0.90[0.65–1.24]
Depression unmedicated 244/11,435
[2.13]
1723/93,896
[1.84]
1.17 [1.02–1.34] 1.10 [0.95–
1.27]
Ns Na
Depression medicated 30/1024
[2.93]
1937/104,307
[1.86]
1.59 [1.11–2.30] 1.41 [0.95–
2.09]
Ns Na
Depression diagnosed 274/12,459
[2.2]
1639/92,872
[1.82]
1.21 [1.06–1.38] 1.13 [0.98–
1.30]
Ns Na
Exclusions, definitions and abbreviations as in Table 2
�Adjusted for parity, smoking, socio-economic status [SES] as Townsend fifth [quintile].
https://doi.org/10.1371/journal.pone.0225133.t005
Antidepressants and perinatal outcomes, including breastfeeding
PLOS ONE | https://doi.org/10.1371/journal.pone.0225133 November 18, 2019 9 / 21
Discussion
To our knowledge, this is the first report, in the published literature, that antidepressants, par-
ticularly high dose SSRIs, depression, particularly medicated depression, and discontinuation
of antidepressants adversely affect breastfeeding rates at 6–8 weeks; the effects of high doses
and discontinuation were not independent of depression. Lower rates of breastfeeding at 6–8
weeks were also apparent with exposure to insulin, AEDs, coumarins, substance misuse and
heavy alcohol use, multiple pregnancy and congenital anomalies (Table B in S2 File).
Intra-uterine exposure to SSRIs, antidepressants and maternal depression were associated
with adverse perinatal outcomes. Birth weight <3rd centile was significantly associated with
antidepressant prescriptions [particularly high dose SSRIs], but depression was not, and the
association was not statistically significant if medication was discontinued after trimester 1.
Gestation length was adversely affected by depression, particularly if medicated, and prescrip-
tion of antidepressants. We confirmed associations between preterm birth and SGA and eco-
nomic deprivation, particularly the most deprived fifth, [55] smoking, [56] and nulliparity,
[57] and between breastfeeding and SES, smoking and parity, [58, 59] but aORs were<2 in
most analyses (Tables C-E in S2 File).
Preterm birth
As elsewhere, depression[20–22, 60], particularly if medicated [20–22,61] was associated with
preterm birth. SNRIs were associated with gestation <37 weeks in unadjusted analyses, par-
tially accounting for the discrepancy between any antidepressant and SSRI exposure for this
outcome. Women who discontinued antidepressants after trimester 1 had no additional risk of
prematurity [Tables 2 and 3]. Meta-analysis of depression and preterm birth gave a random
effects OR close to ours; however, adjusted analysis was not significant. [62] Prematurity was
associated with psychiatric disorders in a Scandinavian cohort [27], and, in contrast with our
findings, SSRI exposure appeared protective; however, different timeframes were used for
Table 6. Breastfeeding at 6–8 weeks (n = 38725).
Exposures Exposed n [%] Unexposed [n [%] Unadjusted
OR
[95% CI]
Adjusted� OR [95%
CI]
NNH Interaction term with
depression variable
SSRI [any N06AB] in trimesters 2 or 3 137/645
[21.24]
12,656/38,080
[33.24]
0.54 [0.45–
0.66]
0.77 [0.62–0.95] 9 [7–12] 1.11(0.72–1.70)
SSRI high dose in trimesters 2 or 3 47/214 [21.96] 12,746/38,511
[33.1]
0.57 [0.41–
0.79]
0.45 [0.23–0.86] 9 [6–18] 2.49[11.13–5.52]
Antidepressant [any N06A] in trimesters 2
or 3
179/806
[22.21]
12,614/37,919
[33.27]
0.57 [0.48–
0.68]
0.81 [0.67–0.98] 10 [8–
13]
1.25[0.86–1.83]
SSRI in trimester 1 but not in trimesters 2
or 3
207/862
[24.02]
12,586/37,863
[33.24]
0.64 [0.54–
0.74]
0.66 [0.51–0.87] 11 [9–
16]
1.59[1.10–2.30]
Antidepressant in trimester 1 but not in
trimesters 2 or 3
376/1619
[23.22]
12,417/37,106
[33.46]
0.60 [0.54–
0.68]
0.70 [0.57–0.85] 10 [9–
13]
1.37[1.04–1.80]
Depression diagnosed and unmedicated in
t2 and t3
1365/5241
[25.87]
11,428/33,484
[34.13]
0.68 [0.67–
0.73]
0.87 [0.82–0.92] 13 [11–
15]
Na
Depression medicated in t2 or t3 102/472
[21.62]
12,691/38,253
[33.18]
0.56 [0.45–
0.69]
0.70 [0.58–0.85] 9 [7–13] Na
Depression diagnosed 1467/5713
[25.7]
11,346/33,012
[34.31]
0.66 [0.62–
0.71]
0.76 [0.70–0.82] 12 [11–
14]
Na
Exclusions, definitions and abbreviations as in Table 2
�Adjusted for SES, as Townsend fifth, parity, smoking and year of birth.
https://doi.org/10.1371/journal.pone.0225133.t006
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SSRI exposure [90 days before LMP to birth], and we found no impact if prescriptions were
restricted to trimester 1. Prematurity was associated with SSRI exposure in a meta-analysis of 8
studies, most of which considered trimester 1 exposure, and the aOR [1.24, 109–1.41] was sim-
ilar to ours. [21] An unadjusted analysis of 13 studies gave a slightly higher OR, 1.55, 1.38–
1.74. [63] Within family analysis found SSRI exposure decreased gestation by 2.3 days, 0.8–
3.8., [64] which is unlikely to be clinically significant or reflected in our findings. In a meta-
analysis, the effect of depression on prematurity was more marked amongst women of lower
SES in the USA and developing countries, but in contrast to our findings, SES did not affect
prematurity. [60]
Maternal stress, short and long-term, increases the risk of pre-term birth, possibly due to
activation of the hypothalamic-pituitary-adrenal [HPA] axis and sympathomimetic responses,
which are intensified in depression, [65,66] congruent with an association between depressive
illness and preterm birth. The corticotrophin releasing hormone [CRH] increase observed in
SSRI treated women may, in part, be due to depressive illness, [16] but higher CRH levels are
reported in women prescribed SSRIs than those with unmedicated depression. [67]
SGA
These findings support the consensus associating intrauterine growth restriction with SSRIs:
[20,22,60,68] SGA <3rd centile was more prevalent amongst those exposed to antidepressants
in trimesters 2 or 3, particularly at higher doses; prevalence was lower if antidepressants were
discontinued after trimester 1 [92 and 45 exposed infants] [69]. Discontinuation of antidepres-
sants was significantly associated with SGA <10th centile, but this outcome is only a modest
predictor of childhood morbidity. [70] Unmedicated depression was not significantly associ-
ated with SGA, confirming meta-analyses suggesting no association between antenatal depres-
sion and SGA [66, 71] [Tables 4 and 5].
SSRI-induced vasoconstriction [11, 14, 15] may explain associations between SSRIs and
low birth weight, growth restriction, [19, 22, 20, 70] persistent pulmonary hypertension, [71,
61] pregnancy-induced hypertension [72], and certain congenital anomalies and stillbirth.
[17] Our findings of increased risk of SGA<3rd centile, particularly at high SSRI doses, but a
statistically insignificant SSRI effect on prematurity are consistent with in vitro embryo studies
reporting fluoxetine dose response effects on cell proliferation, migration and differentiation,
but not the timing of development. [73]
Breastfeeding
Antidepressants or SSRIs after trimester 1, discontinuation, and depression were all associated
with lower breastfeeding rates at 6–8 weeks. Reduction was greater if depression was medi-
cated or high doses of SSRIs were prescribed, but numbers were low [[102 and 47 at 6–8
weeks], and associations with high doses and discontinuation may not have been independent
of depression [interaction term aOR 2.49, 1.13–5.52] [Tables 6 and E in S2 File]. Breastfeeding
initiation is less likely amongst women with depression [OR 0.68, 0.61–0.76] [62], particularly
if co-exposed to antidepressants in trimester 3 [aOR 0.25, 0.11–0.57] [64], [aOR 0.25, 0.11–
0.56] [64], or dispensed antidepressants [aOR 0.63, 0.50–0.80] [74], but we did not locate
reports of breastfeeding at 6–8 weeks.
SSRI [any dose] exposure predicted exclusive formula feeding independently of a history of
depression, suggesting an underlying biological mechanism. SSRIs may delay alveolar secre-
tary activation by 69–86 hours, due to serotonin-dependent changes in tight (inter-cellular)
junctions, [75] thwarting establishment of breastfeeding. SSRI exposure in trimester 3 affects
monoamine metabolism in infants, causing a dose-response increase in restlessness, tremor,
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and incoordination, [10] impeding breastfeeding; this may be the mechanism underlying
delays in fine motor development at 3 years [76] or autistic-like behaviours secondary to
increased serotonin post-partum. [77] Epigenetic changes, activation of the HPA axis and
transfer of cortisol and other mediators to the fetus are associated with both maternal depres-
sion and antidepressants [16,78] and their impacts on neurobehavioural development are diffi-
cult to disentangle. [77] These symptoms, and any SSRI neonatal withdrawal symptoms of
irritability, may impede latching, making breastfeeding painful & difficult, promoting breast-
feeding discontinuation. How insomnia caused by SSRIs [40] affects breastfeeding is
unknown. Effects may be exacerbated by transfer of medication into breast milk: transfer var-
ies with drug, dose, timing of administration and feeding and supplementary formula feeding,
but is ~5–10% of adult SSRI dose. Irritability, restlessness, diarrhoea and suboptimal weight
gain are reported in case series, but reports of developmental delay attributed to lactation have
not been located.[79] Some women were breastfeeding at 6–8 weeks, at all doses, supporting
suggestions that impact may vary with genotype. [80]
Women using prescription medicines are less likely to breastfeed, particularly if there is lit-
tle information about the transfer of the medicine to breastfed infants. [81] Women prescribed
SSRIs at 12 weeks’ gestation are less likely to express intention to breastfeed, [82, 83] which is a
powerful predictor of breastfeeding at discharge. [58] In Wales, linear relationships between
economic deprivation and breastfeeding, [58, 59] and economic deprivation and SSRI pre-
scription in pregnancy, adjusted for diagnosed depression, have been identified. [50] Given
the known benefits of breastfeeding, these new data provide further evidence that prescribing
patterns are contributing to the concentration of the adverse effects of medicines amongst the
poorest. Our findings [NNH 10, 8–13]suggest that successfully targeting women prescribed
antidepressants or with a recorded diagnosis of depression would improve breastfeeding rates
by ~10%, and protect 1.3% of infants from obesity [1.3%, 0.6–1.9% population reduction] and
0.7% of women from breast cancer [0.7%, 0.3–1.1% population reduction]. [84]
Wider context: Addressing inequalities
Preterm birth, SGA and suboptimal breastfeeding remain threats to global health. These must
be minimised before UN targets to reduce neonatal mortality to<10 per 1,000 live births and
the prevalence of non-communicable disease [cardiovascular disease, obesity and type 2 diabe-
tes] can be achieved. [85] Lower family income and education intensify the impact on families
of behavioural and neurodevelopmental sequelae [cerebral palsy, cognitive impairment,
impaired hearing or vision], [86] and the concentration of adverse outcomes and antidepres-
sant prescriptions amongst the most economically deprived intensifies the importance of
using these findings to target support. [50, 17] Women with depression or prescribed antide-
pressants, insulin, AEDs or coumarins or misusing alcohol and other substances need addi-
tional breastfeeding support post-partum, including uninterrupted time with their infants.
The risks of harm from depression [mainly prematurity] should be considered against
those of antidepressant prescription, particularly SGA <3rd centile [NNH 90, 54–274], which
is associated with neonatal mortality, seizures and sepsis. [87] For women with severe depres-
sion the additional risks associated with antidepressants are outweighed by the high risk of
relapse [88]. However, detailed monitoring is warranted. [89] For example, scans in trimester
3 for women prescribed antidepressants in trimesters 2 and 3 would identify growth restric-
tion, and ensure delivery of affected infants where neonatal intensive care is available. [17] Sys-
tematic review suggests that cognitive behavioural therapy [CBT] improves depressive
symptoms [90] as effectively as medication. [91] Randomization of women diagnosed with
depression to SSRI rather than psychotherapy increases the risk of preterm birth, 6.8% vs 5.8%
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aOR 1.17, 1.10–1.25, [21] but further exploration of the impact of talking therapies or discon-
tinuation in early pregnancy on pregnancy outcomes is needed. [92,93]
Limitations and strengths
We acknowledge the limitations of routine health services databases: adherence to prescribed
regimens cannot be ascertained from prescription data [17]. However, in the absence of clini-
cal trials, this detailed analysis of continuation and discontinuation of antidepressants and
depression in pregnancy identifies a population receiving insufficient support.
Incomplete information. Only data recorded by primary care professionals could be ana-
lysed. Hospital, private and internet prescribing, genetic makeup, family history, particularly
paternal family history, recreational drug use, alcohol use and substance misuse are captured
poorly in routine care, fieldwork and databases: however, the Wales database is relatively com-
plete for the last. [17] The high proportion of missing data for BMI precluded incorporation
into multivariate analyses. Ethnicity is considered too sensitive for release to researchers by
Wales’ trusted third parties.
Diagnosing depression. Comparisons with other studies may be complicated by differences
in ascertainment of diagnosis of depression, and the low numbers of hospital admissions. Depres-
sion may be under-reported in primary care records, due to inaccurate diagnosis by primary care
practitioners, [94] fears of ‘labeling’ or stigmatizing, [72] and, possibly, incomplete record transfer
from secondary care. [17] We acknowledge the risks of under-ascertainment or inconsistency
between individual GPs, and the limitations of taking the absence of records as ‘no problems’. The
decision not to time-restrict the diagnosis of depression is based on the depression diathesis
model, [36] and the reluctance of clinicians to repeatedly enter the same diagnoses. Alternative
indications for anti-depressants did not account for the 42% of women, including some women
prescribed higher doses, with no recorded indications for antidepressants. Manifestations of
depression are not routinely and uniformly recorded in healthcare databases, and we were unable
to explain why so many women discontinued their prescriptions, without needing hospitalization
or CMHT contact. However, consideration of interaction terms, medicated and unmedicated
depression, doses, admissions, and discontinuation makes our analyses as robust as possible.
Potential confounding and effect mediation. Like all non-randomised studies, popula-
tion cohort analyses are vulnerable to residual confounding [51, 95]. To address confound-
ing by indication we analysed prescriptions and diagnoses separately and together, and
checked interaction terms. Women diagnosed with depression but not receiving prescrip-
tions may have been relatively unaffected by symptoms, and those continuing into trimes-
ters 2 and 3 or prescribed higher doses may have experienced more severe symptoms,
risking confounding by severity [95]. Exclusion of co-exposed infants from the analysis
reduced confounding by co-exposure: use of insulin, AEDs, coumarins, substances and
alcohol was higher amongst women with depression, medicated and unmedicated, and
adverse perinatal outcomes were more prevalent following these exposures [46–49] [Tables
A and B in S2 File]. We were unable to determine if any adverse outcomes were complicated
by co-exposure to pre-eclampsia or pregnancy-induced hypertension, [24, 26, 96] which
might have prompted preterm induction of labour or caused SGA. Congenital anomalies
are associated with SGA and preterm birth [97, 98], therefore, affected infants were
excluded; associations are previously reported [17].
Multiple testing. We acknowledge the hazards of multiple testing, without correction.
Our independent [predictor] variables are highly correlated. This makes standard adjustments,
such as the Bonferroni method, unduly conservative, risking false negatives. [99] Our findings
are consistent with biological plausibility and the literature.
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Generalization. Data from one European country, where most of the population are in
an EU convergence zone [GDP <75% of the EU mean], cannot necessarily be extrapolated
to different populations, but they evidence the need for national initiatives here and in simi-
lar populations. There were too few infants at <32 weeks’ gestation to draw conclusions, as
elsewhere, [67] but analysis of high dose exposure assists interpretation. The restrictions of
our cohort were due to incomplete GP participation and incomplete data, secondary to
practices’ technical failures or women moving to practices not covered by SAIL [33]. Rather
than any participant self-selection bias, the breastfeeding outcome was restricted by varia-
tions in recording practices across the seven Health Boards in Wales. Had a volunteer bias
been operating, we should have expected to see older, less deprived women over-repre-
sented [100]; this was not the case. Too few women were hospitalised for mental health
problems to draw conclusions.
Drawing causal inferences from observation data may be imprudent. However, using these
findings to target support is justified, reflecting that, for most adverse outcomes, retrospective
analyses yield lower odds or risk ratios than prospective studies. [101]
Conclusion and implications: Support before, during and after
pregnancy
This analysis identified a population vulnerable to adverse outcomes, including exclusive for-
mula feeding at 6–8 weeks. Antidepressants, particularly high dose SSRIs, increased the preva-
lence of SGA<3rd centile, whereas depression, particularly if medicated, affected duration of
gestation. Like others [69], we found little evidence that antidepressants are protective. Discon-
tinuing antidepressants after trimester 1 appeared to reduce risks of SGA<3rd centile, but
infants remained vulnerable to exclusive formula feeding. The concentration of prescribing
and adverse outcomes amongst the economically disadvantaged should encourage pre-con-
ception monitoring in tandem with review of antidepressants and non-pharmacological thera-
pies. These data indicate that prescription of antidepressants is an important marker for
adverse outcomes, easily identified in primary care records. This could, and should, be used to
trigger additional monitoring, including third trimester scans or alternative continuous moni-
toring technology to detect SGA. Using prescriptions to target care before, during and after preg-
nancy warrants exploration as a strategy to optimize breastfeeding at 6–8 weeks, and all
perinatal outcomes [17].
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